The development of the Immunforte product line, which currently includes two products containing various fungal extracts, Resveratrol and vitamin C, is the result of years of research by Professor Dr. József Fachet, Doctor of the Hungarian Academy of Sciences, immunologist and cancer researcher.
The active ingredients were selected on the basis of decades-long international research carried out in conjunction with Professor Dr. Goro Chihara, senior researcher at the Tokyo-based National Cancer Institute. Due to their exceptional effects on the immune system, these 100% natural ingredients are already used as registered drugs for the treatment of Japanese tumour patients.
Based on research findings, the Immunforte products were developed with consideration to two fundamental observations:
Therefore, it is important to stimulate all immune responses (cell types, responses, active ingredients) that may block the growth of or destroy the different tumour types.These immune responses can attack the different tumours, and block tumour growth and metastasis in synergy with various types of cells, responses and immunological ingredients.
The product contains 100% natural active ingredients, which can be completely absorbed by the body. The expected beneficial effects of the products are:
This product line was first registered and introduced as a dietary supplement in the second half of 2011. We are planning to start the process of registration as an OTC (over-the-counter) drug after putting the products on the market. Future plans include the development of new products.
After launching sales in Hungary, more remote plans include registration and distribution in the EU and then in the US. With support from medical experts, the product can be presented to the international medical community.
Each year around 66,000 new cancer cases are diagnosed, and 33,000 to 34,000 people die from this disease in Hungary. According to estimates, 300,000 to 400,000 Hungarians suffer from cancer. Apart from this group of patients, prevention represents a major sales opportunity. Based on the relevant data, both the development costs and the expected turnover will be around HUF 100 million on the domestic market alone.
The penetration of external markets offers further opportunities.
Currently QUAESTOR Pte. Ltd. is the exclusive investor of Dr. Fachet LLC.
Potential areas of cooperation: